Differentiation of cerebral metastases of lung cancer using apparent diffusion coefficient (ADC) maps

• Conditions: C34; C79.3; Malignant neoplasm of bronchus and lung; Secondary malignant neoplasm of brain and cerebral meninges

• Registration Number: DRKS00023016
• Lead Sponsor: niversitätsmedizin Göttingen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2020-08-30
• Study Start: 2020-09-07
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 600

Inclusion Criteria

Patients with pathologically confirmed SCLC or NSCLC and an MRI of the brain, regardless of the MRI manufacturer or the field strength. It must only contain (i) a T1-weighted sequence with contrast agent (CA), (ii) a T2-weighted sequence for detecting zystic parts and (iii) a DWI Sequence with ADC Mapping.

Exclusion Criteria

Patients are excluded, if
(1) brain metastasis are not detected by MRI, (2) the size of the found solid tumour parts were not large enough (<0.25 cm²) for measurements or (3) more than one tumour origin was known at time of MRI.
Brain metastases with large intratumoral haemorrhage (>50% of the solid tumour part) were excluded.

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
We want to analyzed, if (i) a reliable differentiation between SCLC and NSCLC using ADC maps is possible

Secondary Outcome Measures

Name	Time	Method
and, (ii) if ADC values under systemic therapy can be used as therapy control.